amifampridine has been researched along with Angina Pectoris, Variant in 1 studies
Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
Angina Pectoris, Variant: A clinical syndrome characterized by the development of CHEST PAIN at rest with concomitant transient ST segment elevation in the ELECTROCARDIOGRAM, but with preserved exercise capacity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uchida, Y | 1 |
| Nakamura, F | 1 |
| Tomaru, T | 1 |
| Sumino, S | 1 |
| Kato, A | 1 |
| Sugimoto, T | 1 |
1 other study available for amifampridine and Angina Pectoris, Variant
| Article | Year |
|---|---|
Phasic contractions of canine and human coronary arteries induced by potassium channel blockers.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Aminopyridines; Angina Pectoris, Variant; Animals; Arte | 1986 |